Back to results
CompletedPhase 4

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

NCT01529619

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novartis Investigative Site

Nagoya, Aichi-ken, Japan

+10 additional locations

View on ClinicalTrials.gov
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors — TrialFind